MARKET

ANAB

ANAB

Anaptysbio Inc
NASDAQ
25.92
-0.76
-2.85%
After Hours: 25.92 0 0.00% 16:33 07/18 EDT
OPEN
26.73
PREV CLOSE
26.68
HIGH
26.92
LOW
25.84
VOLUME
334.04K
TURNOVER
--
52 WEEK HIGH
41.31
52 WEEK LOW
12.21
MARKET CAP
761.54M
P/E (TTM)
-5.3540
1D
5D
1M
3M
1Y
5Y
1D
AnaptysBio, Inc.'s (NASDAQ:ANAB) Share Price Not Quite Adding Up
Simply Wall St · 4d ago
AnaptysBio: Potential Promise, But Some Cause For Skepticism
Seeking Alpha · 6d ago
Weekly Report: what happened at ANAB last week (0707-0711)?
Weekly Report · 6d ago
Weekly Report: what happened at ANAB last week (0630-0704)?
Weekly Report · 07/07 09:15
Analysts Offer Insights on Healthcare Companies: AnaptysBio (ANAB) and Capricor Therapeutics (CAPR)
TipRanks · 07/02 09:05
Weekly Report: what happened at ANAB last week (0623-0627)?
Weekly Report · 06/30 09:15
Weekly Report: what happened at ANAB last week (0616-0620)?
Weekly Report · 06/23 09:14
AnaptysBio Holds 2025 Annual Stockholders Meeting
TipRanks · 06/17 20:37
More
About ANAB
AnaptysBio, Inc. is a clinical-stage biotechnology company. The Company is focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. The Company’s lead program, Rosnilimab, is a depleter and agonist targeting PD-1+ T cells, is in a Phase IIb trial for the treatment of rheumatoid arthritis and in a Phase II trial for the treatment of ulcerative colitis. The Company’s pipeline also includes ANB033, a CD122 antagonist, and ANB101, a blood dendritic cell antigen 2 (BDCA2) modulator, in Phase I trials. It has also discovered multiple therapeutic antibodies licensed to GSK in a financial collaboration for immuno-oncology, including a PD-1 antagonist (Jemperli (dostarlimab-gxly)) and a TIM-3 antagonist (cobolimab, GSK4069889). Rosnilimab is an IgG1 antibody that directly targets PD-1+ T cells, resulting in their depletion or agonism, impacting pathogenic drivers of autoimmune and inflammatory diseases.

Webull offers AnaptysBio Inc stock information, including NASDAQ: ANAB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ANAB stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ANAB stock methods without spending real money on the virtual paper trading platform.